Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma

Respiratory Medicine

Volumn 101, Issue 10, 2007, Pages 2182-2191

  Vermeulen, J H ^a   Gyurkovits, K ^b   Rauer, H ^c   Engelstatter R ^c  

^a Institute of Pulmonology ^*  (South Africa)

^b Institute of Pulmonology   (Hungary)

^c ALTANA PHARMA AG   (Germany)

Author keywords

Adolescent; Asthma; Budesonide; Ciclesonide; Cortisol

Indexed keywords

ANTIHISTAMINIC AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; CREATININE; HYDROCORTISONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; THEOPHYLLINE;

ABNORMAL LABORATORY RESULT; ADOLESCENT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ECG ABNORMALITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE URINE LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SYMPTOM; THRUSH; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PREGNENEDIONES; QUALITY OF LIFE; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 34548329947     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.05.006     Document Type: Article

References (38)

1. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 109 (2002) S482-S489
2. ISAAC. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 12 (1998) 315-335
3. Sennhauser F.H., Braun-Fahrlander C., and Wildhaber J.H. The burden of asthma in children: a European perspective. Paediatr Respir Rev 6 1 (2005) 2-7
4. Masoli M., Fabian D., Holt S., and Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 5 (2004) 469-478
5. Global Initiative for Asthma (GINA). National Institutes of Health, National Heart, Lung and 338 Blood Institute. 〈http://www.ginasthma.com〉, 2005.
6. National Institutes of Health (NIH). National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics. J Allergy Clin Immunol 2002;110:S141-219.
7. Simons F.E. Benefits and risks of inhaled glucocorticoids in children with persistent asthma. J Allergy Clin Immunol 102 5 (1998) S77-S84
8. Lipworth B. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 159 9 (1999) 941-955
9. Newman S., Salmon A., Nave R., and Drollmann A. High lung deposition of (99m)Tc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 100 3 (2006) 375-384
10. Dietzel K., Engelstätter R., and Keller A. Ciclesonide: an on-site activated steroid. Prog Respir Res 31 (2001) 91-93
11. Nave R., Zech K., and Bethke T.D. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 61 3 (2005) 203-208
12. Richter K., Kanniess F., Biberger C., Nave R., and Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 45 2 (2005) 146-152
13. Engelstaetter R., Escher A., and Haefner D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J 26 Suppl. 49 (2005) 255s
14. Rohatagi S., Luo Y., Shen L., et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 12 3 (2005) 201-209
15. Postma D.S., Sevette C., Martinat Y., Schlosser N., Aumann J., and Kafe H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 17 6 (2001) 1083-1088
16. Chapman K.R., Patel P., D'Urzo A.D., et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 60 3 (2005) 330-337
17. Langdon C.G., Adler M., Mehra S., Alexander M., and Drollmann A. Once-daily ciclesonide 80 or 320 μg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 99 (2005) 1275-1285
18. Pearlman D., Berger W., Kerwin E., LaForce C., Kundu S., and Banerjee D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 116 6 (2005) 1206-1212
19. Szefler S., Rohatagi S., Williams J., Lloyd M., Kundu S., and Banerji D. Ciclesonide, a novel inhaled steroid, does not affect HPA-axis function in patients with moderate-to-severe persistent asthma. Chest 128 (2005) 1104-1114
20. Gelfand E.W., Georgitis J.W., Noonan M., and Ruff M.E. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 148 3 (2006) 377-383
21. Declaration of Helsinki revised versions Tokyo (1975), Venice (1983), Hong Kong (1989), Somerset West (1996). The World Medical Association.
22. Fishman G., and Moore L. A statistical evaluation of multiplicative congruential random number generators with modulus 231-1. JASA 77 (1982) 129-136
23. Standardization of Spirometry, 1994. Update, American Thoracic Society. Am J Respir Crit Care Med 152 3 (1995) 1107-1136
24. Townsend M., Feeny D.H., Guyatt G.H., Furlong W.J., Seip A.E., and Dolovich J. Evaluation of the burden of illness for pediatric asthmatic patients and their parents. Ann Allergy 67 (1991) 403-408
25. Juniper E.F., Guyatt G., Feeny D., Ferrie P., Griffith L., and Townsend M. Measuring quality of life in children with asthma. Qual Life Res 5 (1996) 35-46
26. Ebbutt A.F., and Frith L. Practical issues in equivalence trials. Stat Med 17 15-16 (1998) 1691-1701
27. Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung and Blood Institute. NHLBI/WHO workshop report, 2003.
28. Boulet L.P., Drollmann A., Magyar P., et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 100 5 (2006) 785-794
29. Niphadkar P., Jagannath K., Joshi J.M., et al. Comparison of the efficacy of ciclesonide 160 μg QD and budesonide 200 μg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther 27 11 (2005) 1752-1763
30. Buhl R., Vinkler I., Magyar P., et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 19 6 (2006) 404-412
31. Ukena D, Biberger C, Steinijans V, et al. Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 2006, in press.
32. Pedersen S., Garcia M.L., Manjra A., Theron I., and Engelstatter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 41 10 (2006) 954-961
33. Magnussen H., Hofman J., Novakova B., et al. Ciclesonide 80 mcg once-daily is as effective as fluticasone propionate 88 mcg twice-daily in the treatment of persistent asthma. J Allergy Clin Immunol 115 2 (2005) S4
34. Okelo S.O., Wu A.W., Krishnan J.A., Rand C.S., Skinner E.A., and Diette G.B. Emotional quality-of-life and outcomes in adolescents with asthma. J Pediatr 145 4 (2004) 523-529
35. Cohen R., Franco K., Motlow F., Reznik M., and Ozuah P.O. Perceptions and attitudes of adolescents with asthma. J Asthma 40 2 (2003) 207-211
36. Derom E., van De Velde V., Marissens S., Engelstätter R., Vincken W., and Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 18 5 (2005) 328-336
37. Lipworth B.J., Kaliner M.A., LaForce C.F., et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 94 4 (2005) 465-472
38. Nave R., Bethke T., Marle Sv., and Zech K. Pharmacokinetics of [14C] ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 43 7 (2004) 479-486